A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...

Nonurinary sodium excretion in afebrile cirrhotic patients without diarrhea is approximately 10 mmol/day. [13] Patients with ascites on no diuretics commonly have renal sodium excretion of < 20 ...

近年来，对脑损伤的研究引起了科学家们极大的关注，尤其是理解与人类神经性疾病相关的细胞和分子改变，在这一背景下，对不同临床生物标志物的研究就有望揭示引起大脑损伤的多种不同的病理学过程。近日，一篇发表在国际杂志 Chinese Medical ...

前言“慢加急性肝衰竭（ACLF）主题月评”是中国慢（加急）性肝衰竭联盟受《国际肝病》编辑部邀请，制作的ACLF相关学术月评专栏。本专栏每月以ACLF某一特定领域为主题展开，旨在普及ACLF的概念及意义、帮助读者快速了解有关领域的进展。希望本专栏对无论 ...

Is your couch potato lifestyle killing your liver? Find out how liver disease, particularly NAFLD, is affecting millions and ...

Beyond the rise in Nrf2, C. molmol resin treatment also reduced protein tumour necrosis factor-alpha (TNF-α), which is known to be high in the serum of cirrhotic patients, a condition in which ...

First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...

Of the treatment options available for patients with hepatocellular carcinoma (HCC), partial hepatectomy offers the greatest chance of a cure; however, it can only be used for patients with good ...

Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, into Phase III trials for treating MASH ...

In 2024, The Food and Drug Administration in the US approved resmetirom, a liver-targeted thyroid hormone receptor ...

It affects around 60 per cent of people with cirrhosis within 10 years of their diagnosis, and the two-year survival rate is 50 percent. Causes Cirrhotic ascites develop when blood pressure in the ...

With an 8-week treatment duration, data from the lead-in cohort of non-cirrhotic patients showed a 97% SVR12 rate in efficacy ...